SCHEDULE 13G/A: Perceptive Advisors Discloses 4.5% Passive Stake in RAPT Therapeutics

Perceptive Advisors LLC and its affiliates have reported a 4.5% beneficial ownership stake in RAPT Therapeutics, Inc., holding 5,880,000 shares of common stock as of December 31, 2024.

Summary

• Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") beneficially own 5,880,000 shares of RAPT Therapeutics, Inc. common stock.
• This ownership represents 4.5% of the Issuer's outstanding common stock.
• The percentage is calculated based on 132,006,828 outstanding shares of Common Stock, as reported in RAPT Therapeutics' prospectus filed on January 28, 2025.
• The Master Fund directly holds the 5,880,000 shares, with Perceptive Advisors serving as its investment manager and Joseph Edelman as the managing member of Perceptive Advisors.
• All Reporting Persons share voting and dispositive power over the 5,880,000 shares.
• The filing is an Amendment No. 5 to a Schedule 13G, indicating a routine update to a passive investment position.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing beneficial ownership. It does not contain information that would significantly alter the perceived value or outlook of the company, thus indicating a neutral sentiment.

Positives

• A prominent life sciences investment firm, Perceptive Advisors, maintains a significant beneficial ownership stake in RAPT Therapeutics, indicating continued investment interest in the company.

Negatives

• The beneficial ownership percentage of 4.5% is below the 5% threshold, which, depending on prior filings, could indicate a reduction in proportional stake, potentially due to share dilution or a partial divestment, though the document does not specify the reason for the current percentage.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding RAPT Therapeutics' future operations or financial performance.

Industry Context

Perceptive Advisors is a prominent investment firm specializing in the life sciences sector. Their continued significant, albeit passive, stake in RAPT Therapeutics, a biotechnology company, reflects ongoing investor interest in the biopharmaceutical industry, particularly in companies with potential therapeutic pipelines.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, which can influence investor perception and confidence.

Key Dates

Keywords

RAPT Therapeutics, Perceptive Advisors, Joseph Edelman, beneficial ownership, Schedule 13G, biotechnology, pharmaceuticals, investment fund, common stock